Overview

Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Bispecific
Blinatumomab
Dexamethasone